Updated with a link to the retatrutide price estimate.
No, but Lilly filed twenty new trademarks in a month and nineteen of them are built on reta or ret. Here is what that tells you, and what it does not.
Retatrutide status, checked September 4, 2026: FDA approved: No · FDA filing: planned Q1 2027 · Brand name: not announced · US price: not announced, though I have worked out what I expect it to cost.
I write about this molecule’s grey market and the lawsuits around it often, so when Lilly filed a batch of new trademarks on September 2, I pulled the whole file out of the USPTO database. Nobody outside Lilly knows what retatrutide will be sold as. But there is a lot more on the record than there was a month ago.
Does retatrutide have a brand name yet?
No. Lilly has not announced one. It is still called retatrutide, its nonproprietary scientific name, and LY3437943, the in-house development code. Neither of those is a brand.
What changed is the filing record. On three days between August 4 and September 2, Lilly filed twenty new US trademark applications, and nineteen of them are built on reta or ret. Before August 4 the company owned exactly one live mark containing reta, KORPRETA, filed back in 2023.
All are in Class 005, the pharmaceutical class, and all are intent-to-use filings, the kind you make for a name you have not sold anything under yet. Every one is still marked “awaiting examination,” so no examining attorney has looked at it.
Get the next one in your inbox
I cover the latest GLP-1 trials and access changes weekly. Free, no spam, unsubscribe whenever.
Which trademarks could be the retatrutide brand name?
The applications themselves will not tell you. Lilly describes the goods either as “pharmaceutical preparations; vaccines for human use” or as a list of roughly forty-five conditions running from alcohol use disorder to vision loss. Both are boilerplate the company puts on its pharmaceutical filings, and neither says retatrutide anywhere. A Class 044 filing, for medical information services, has to describe the disease it covers, and Lilly’s 044 filings name one condition rather than forty. There is no reta filing in Class 044. When one appears, that is the document worth reading.
One thing does separate them. Lilly buys the matching .com before it files the trademark, and it did exactly that with Zepbound: zepbound.com was registered on April 13, 2022, and the application went in the next day. The registrant name is withheld on the new domains, so what follows is a fingerprint rather than a signature. Eleven of the nineteen sit at GoDaddy Corporate Domains on the same two nameservers as retatrutide.com, which Lilly has held since 2022. The earliest three, vynnreta.com, vymreta.com and wynnret.com, were registered on April 21, three and a half months before the first application. The other eight are on consumer registrars and show no sign of being Lilly’s.
| Mark | Filed | Domain at Lilly’s registrar |
|---|---|---|
| VYNRETA, VYNNRETA | Aug 4 | Yes (Apr 21 and Jul 31) |
| VYMRETA, VYMMRETA | Aug 4 | Yes (Apr 21 and Jul 31) |
| RETAHNOVA, RETAHVERA, VERAHRETA | Aug 4 | Yes (Jul 31) |
| HIRETA | Aug 4 | No, taken since 2016 |
| YEZRETA, YEZRET, YEZZRETA | Aug 5 | No, taken hours after filing |
| VOYRETA, ONERETA, REALLRETA, WYNNRET | Sep 2 | Yes (Apr 21 to Sep 1) |
| ONRETA, REALRETA, TRURETA, RETANOVA | Sep 2 | No, all taken earlier |
That puts the vyn and vym pairs, VYNRETA and VYNNRETA, VYMRETA and VYMMRETA, in the group carrying Lilly’s fingerprint at the registrar as well as at the USPTO. The yez group is the one that breaks the pattern. YEZRETA, YEZRET and YEZZRETA were all registered on the evening of August 5, the day Lilly filed them, within two minutes of each other, through a Hong Kong registrar, and they point at a domain marketplace. Whoever registered them got there the same evening the filing became public, and listed them for sale. So the name that gets picked as the favourite online is the one Lilly does not hold the address for.
Lilly sells tirzepatide under two names, Mounjaro for diabetes and Zepbound for weight loss. Retatrutide is in trials for three separate uses, so more than one of these names could end up on a label.
What happened the last time Lilly named a drug like this
On a single day in April 2020, Lilly filed six trademarks built on zep, the syllable in the middle of tirzepatide: ZEPJURNI, RYTEZEP, TAYZEPTRO, YAZEPSA, APMYZEP and JETZEPICA. All six are dead. Two more, ZEPLIFY and IZEPLIFY, followed in February 2021 and also died. The name Lilly actually used, Zepbound, was filed on its own in April 2022 and approved in November 2023.
Mounjaro followed a similar sequence. That mark was filed in November 2019, two and a half years before approval, and the near-miss spellings that protect it were not filed until December 2021, after the decision was made.
So I would not read this batch as a decision. Filing a dozen near-identical names in one go is what clearing candidates looks like. When Lilly has picked, it files one name by itself, and it has not done that here. The FDA also reviews the proposed name separately from the drug and can reject it outright, which is a second reason a filing is not a decision.
Who makes retatrutide?
Eli Lilly, the same company behind Mounjaro, Zepbound and Trulicity. Retatrutide is a triple agonist, meaning it acts on three gut-hormone receptors (GLP-1, GIP and glucagon) instead of the one or two that older drugs in this class target. Lilly has reported positive results from five Phase 3 trials and says the FDA filing it plans for the first quarter of 2027 will cover obesity, obstructive sleep apnea and knee osteoarthritis pain. I went through how it compares with Zepbound separately; it looks like a real step up.
Lilly also wants retatrutide treated as a biologic, and the FDA says it is a regular drug, the same category as Mounjaro and Zepbound. Lilly sued over that, and oral argument at the Seventh Circuit is set for September 24, 2026. I went through that fight in a separate post.
The reta brands already on sale are not Lilly’s
Trureta is one of the names Lilly filed on September 2. The domain has been registered since July 25 by somebody behind a privacy service, and it forwards to a Shopify store selling “40 mg prefilled Retatrutide pens for laboratory research use.” Lilly filed for that trademark five weeks after the store took the address.
Supplement companies are filing reta names too. Hi-Tech Pharmaceuticals filed RETASLIM in August for dietary supplements, GS Labs filed RETABOLIC for weight-management supplements, and a Wyoming company filed RETA MD covering telemedicine and weight-loss programs. None of those filings is Lilly’s, and none of them is retatrutide. I have written before about what is actually in those vials and why none of it is legal to buy for personal use, and a brand-sounding name is one more thing sellers use to look official.
A brand name normally becomes public at or near approval. Lilly says it will file in early 2027, so I would not expect a decision before the second half of 2027, and it could slip. I track the running numbers for every drug in this class on my GLP-1 pipeline tracker, and I check Lilly’s trademark filings daily now, so this page will change the day a name is announced. It keeps this same web address when it does. Until then, a specific name attached to retatrutide is somebody’s guess or somebody’s domain investment, not Lilly’s decision. I ran the same query against Novo Nordisk, which has eleven invented names on file and has not announced one for CagriSema either: does CagriSema have a brand name yet.